Home » Newsletters » BioWorld Science

BioWorld Science

June 21, 2021

View Archived Issues

LZM-005 shows safety, potent activity in phase I study in HER2-positive metastatic breast cancer

Phase I dose-escalation data for SAR-439459 as monotherapy or in combination with cemiplimab

Etavopivat improves hematologic and hemolytic parameters in patients with sickle cell disease

Pfizer studies PF-07202954 in phase I healthy volunteer trial for NAFLD

Targeting FKBP5 lowers huntingtin levels by inducing autophagy in Huntington's disease models

OTUD7A: a novel therapeutic target for Ewing sarcomas with EWS-FLI1 fusions

Canopy Growth divulges new cannabinoid CB1 and CB2 receptor modulators

Bayer and DKFZ synthesize new DGKA inhibitors

Chinese researchers present CEACAM5- and CD3-targeting antibodies for cancer

Mavorixafor and ibrutinib in WM with MYD88 and CXCR4 mutations

NIH grant supports Praetego's development of AGE inhibitors

Evergreen prepares for phase II trial of COVID-19 candidate EG-009A

Ociperlimab shows safety and preliminary antitumor activity in combination with tislelizumab

French clearance for phase I/IIa trial of PBP-1510 for pancreatic cancer

LncRNA HOST2 is a diagnostic marker in TNBC

Topline phase II data for nezulcitinib in patients hospitalized with ALI due to COVID-19

Tonix to study TNX-102 SL for the treatment of long COVID syndrome

Period piece: endometrial organoids from menstrual blood

SIGMAR1 mRNA identified as biomarker of response in phase II study of blarcamesine

First subject enrolled in OLYMPIA phase II study of OC-01

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...